COMPASS Pathways (NASDAQ:CMPS) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Key Points

• COMPASS Pathways reported a quarterly earnings per share (EPS) of ($0.38), missing analysts' estimates of ($0.37) by $0.01.
• After the earnings announcement, shares of COMPASS Pathways traded down 0.2%, reaching a price of $4.34.
• Analysts have varying price targets for the stock, with a consensus target price of $17.00 and ratings ranging from "hold" to "buy."

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01), Zacks reports.

COMPASS Pathways Price Performance

CMPS traded up $0.28 during trading on Monday, reaching $4.62. 856,972 shares of the stock were exchanged, compared to its average volume of 1,834,030. The business's 50 day moving average price is $3.99 and its two-hundred day moving average price is $3.80. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.82 and a quick ratio of 8.82. The company has a market capitalization of $431.79 million, a price-to-earnings ratio of -2.52 and a beta of 2.16. COMPASS Pathways has a 1 year low of $2.25 and a 1 year high of $8.54.

Institutional Trading of COMPASS Pathways

An institutional investor recently raised its position in COMPASS Pathways stock. Royal Bank of Canada grew its stake in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 49.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,446 shares of the company's stock after acquiring an additional 29,733 shares during the quarter. Royal Bank of Canada owned about 0.10% of COMPASS Pathways worth $256,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 46.19% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on CMPS. HC Wainwright restated a "buy" rating and issued a $45.00 price target on shares of COMPASS Pathways in a research note on Tuesday, July 15th. Canaccord Genuity Group restated a "buy" rating and issued a $15.00 price target on shares of COMPASS Pathways in a research note on Friday. Cantor Fitzgerald restated an "overweight" rating and issued a $12.00 price target on shares of COMPASS Pathways in a research note on Tuesday, May 27th. Finally, Evercore ISI reiterated an "in-line" rating and set a $6.00 target price (down from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $17.00.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.